We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Genomic Aberrations of Asian Gastric Cancer Discovered

By LabMedica International staff writers
Posted on 19 Jul 2015
The fusion of two genes gives rise to the destruction of the stomach surface barrier, resulting in gastric acids affecting the stomach tissues; moreover, this fusion also hampers wound-healing.

Structural changes of chromosomes or genome rearrangements can result in gene fusions with properties that can cause cancer and the three-dimensional organization of the genome, known as the chromatin structure, plays a role for the generation of rearrangements.

Scientists at The Agency for Science, Technology and Research (A*STAR, Singapore) and their colleagues used a technique known as DNA paired-end-tag (DNA-PET) whole genome sequencing, to analyze15 gastric cancers (GCs) from Southeast Asians, and observed that rearrangements were enriched in regions of active genes. More...
They subsequently screened 100 GCs for certain fusion genes that were discovered in the 15 GCs.

Through the sequencing, the scientists identified seven hotspots across the genome which had many rearrangements as well as 136 gene fusions. In three out of the 100 GC cases, they found recurrent fusions between Claudin 18 (CLDN18), a tight junction gene, and Rho GTPase Activating Protein 26 (ARHGAP26), a gene encoding a Ras homolog gene family, member A (RHOA) inhibitor. The functions of both genes are important for a tight inner surface (epithelium) of the stomach. Epithelial cell lines expressing the fused genes CLDN18-ARHGAP26 displayed a dramatic loss of epithelial phenotype and long protrusions indicative of epithelial-mesenchymal transition (EMT). Overall, CLDN18-ARHGAP26 mediates epithelial disintegration possibly leading to leakage of gastric acids, and the fusion might contribute to invasiveness of tumors once a cell is transformed.

Walter Hunziker, PhD, a senior coauthor of the study said, “CLDN18 is a critical component of the gastric epithelial barrier. Fusion of ARHGAP26 to CLDN18 not only interferes with the tethering of CLDN18 to the actin cytoskeleton, but could also affect the actin cytoskeleton by inhibiting RHOA at the wrong location, thereby compromising barrier integrity. The resulting inflammation and gastritis are well known risk factors for gastric cancer.” The study was published on July 2, 2015, in the journal Cell Reports.

Related Links:

The Agency for Science, Technology and Research 



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.